wedbush calendar upcom event
initi neutral lumber inflat potenti weak industri
initi coverag univers forest product inc neutral rate pt neutral rate
base three catalyst first recent weak domest manufactur measur new shipment durabl
good may exacerb corona viru issu could neg industri segment second believ
consensu gross margin estim high rise lumber price environ third realign
segment focus end user geograph segment may near-term headwind next catalyst
ep releas market close discuss page
one step forward step back downgrad neutral
wedbush view present updat data newli nomin preclin program aml
first look compani develop program hereditari angioedema keyston symposia engin
genom confer egc week banff canada compani expect name develop candid
appreci opportun ad opportun valuat
compani also discontinu antitrypsin defici aatd primari hyperoxaluria type see latest
compani pipelin figur remov aatd valuat reduc price target
lower rate neutral given current trade level
enter ex-vivo recent name cell develop candid aml target
known aml antigen wilm tumor compani lead tcr select healthi donor cell anti-tumor
activ primari aml blast figur employ insert transgen tcr trac locu
achiev homogen via remov endogen tcr chain figur could consist
reduc unwant alloreact graft versu host diseas gvhd construct reduc unwant cell
prolifer reduc alloreact ntla cell product character cytotox primari aml
blast demonstr cytotox bone marrow cell figur look forward compani
anticip ind file also recent public stadtmauer et al engin
cell ph studi patient melanoma sarcoma support feasibl ntla
studi use similar tcr engin strategi delet trac trbc insert
tgtcr extra delet encod durabl engraft report modifi
cell persist month
enter rare hereditari condit often caus mutat code aberr esteras
inhibitor inhibitor defici lead inflamm pain via uncontrol gener plasma kallikrein serin
proteas releas bradykinin caus vascular leakag angioedema episod occur averag everi week
episod day untreat individu life-threaten approxim peopl affect
chronic treatment option avail limit attenu androgen danazol
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
high discontinu rate plasma-deriv inhibitor cinryz estim annual cost
tax iv administr everi day plasma kallikrein inhibitor also approv lanadelumab shire
limit discontinu amen dose regimen mg sq everi week ntla potenti answer
market opportun estim see figur engin gene edit knock kallikrein
gene earli result non-human primat nhp present egc show effect knockdown kallikrein
protein level reduct kallikrein activ least month figur similar plasma kallikrein reduct
observ human mice expect name program candid regeneron
cover option enter co/co agreement program
downgrad rate neutral outperform decreas pt sum-of-part
valuat base multipl royalti revenu estim attr aml discount back
chang price target attribut remov opportun aatd valuat
attribut much valu program previous view aatd largest opportun
due signific commerci opportun wholly-own statu compar larg market valuat increas
incorpor opportun anticip could reach market
model address patient preval popul us anticip peak penetr given
potenti cur impact genet therapi assum price price standard care
option model annual instal period also mid-decemb exercis right
attr co-develop co-promot agreement return share back
increas valuat program lastli adjust expect price order better
reflect therapi market increas program valu valuat tabl financi model
lower rate estim pt lower expect
compani indic earn call expect see flat leas relat revenu
expect growth manag servic incom hard area expand reduc price target
given modest upsid target like challeng revenu growth reduc rate
op neutral
fiscal financi focu clinic execut
remain one top pick given continu emerg ph data across sever differ cohort
view compani full clinic execut mode see share driven multipl ph readout well
advanc secondari asset reiter outperform rate price target
report fiscal net loss wider estim
share note discrep mostli attribut higher expect expens compani expand
clinic program compani end calendar year cash equival includ net proce
recent equiti rais novemb manag guid current cash resourc fund on-going
oper
ph prostat cancer updat ciforaden gu
poster present gu crv highlight ciforaden monotherapi combin activ mcrpc
mcrpc arm on-going ph studi began enrol patient octob on-going arm enrol rcc
patient patient advanc mcrpc evalu data cut receiv ciforaden monotherapi
mg twice daili receiv ciforaden atezolizumab mg ciforaden twice daili mg iv
atezolizumab note patient popul highli refractori fail median three prior therapi
viscer metastas data poster shown report
although earli view current dataset underwhelm clinic rational evalu antagonist come
astrazeneca show one confirm pr one sd treat monotherapi evalu patient
one pr one cr two sd evalu patient combin durvalumab note pembrolizumab
demonstr orr monotherapi refractori mcrpc patient ph studi atonarkai
et al crv expect present addit data on-going cohort current
incorpor potenti revenu mcprc model current await clear path forward
leav price target unchang
clinic stage biotech compani develop microrna therapeut compani two product
clinic develop treatment autosom domin polycyst kidney diseas adpkd phase
treatment alport syndrom phase partner sanofi februari regulu announc
reiniti multipl ascend dose anticip complet top-line data shortli
thereaft compani anticip initi addit short-term dose studi assess safeti
pharmacokinet biomark pharmacodynam activ part phase program fda outlin partial
clinic hold two part requir re-initi mad studi addit requir
support long term dose studi data multipl ascend dose mad studi short-term dose studi well
addit non-clin work intend address remain partial clinic hold requir long term dose
view fda remov partial clinic hold re-initi mad studi posit stock
look forward updat
phase mad studi top-line result
reiter outperform rate share new target print held littl suspens manag
previous announc number revenu data point well guidanc target backdrop
look ahead catalyst line appear solid phase expans cohort data expect
well potenti phase prophylact steroid data over-the-counter defici beyond data updat
also hold pdufa lc-faod incorpor actual result laps partial discount
period price target move previous continu like potenti share move higher
cours remain outperform rate share
wedbush view increas pt follow recent public impress initi ph data
takeda collabor md armor cell candid believ de-risk
fate platform induc pluripot stem-cel ipsc -deriv nk ink cell platform
boston april
wedbush view pre-announc tight sale estim rang januari see note estim figur
met expect quarterli xpovio sale sale broadli distribut across uniqu
prescrib physician healthcar account key catalyst share remain upcom readout
ph boston studi selinexor multipl myeloma mm expect end april studi evalu
qw selinexor combo bortezomib low dose dexamethason svd biw bortezomib low dose
dexamethason current model month benefit xpovio eight cycl increas month
benefit add anoth valuat benefit also drive increas market penetr current
model market penetr see sensit analysi figur landscap earlier line mm remain fierc
competit opinion selinexor benefit would surprisingli larg dramat move share
long-term regard european xpovio approv compani request grant three-month extens
ema respond outstand question surround applic selinexor heavili pretreat mm
set base ph storm studi result decis ema expect continu
expect fda decid snda file selinexor r/r dlbcl wait result boston plan
file ema expand label dlbcl earlier mm set develop karyopharm aim
initi new clinic trial year expect trial kick year includ confirmatori ph trial selinexor dlbcl
support acceler approv ph trial selinexor dlbcl combin
approv agent provid insight suitabl set drug ph trial colorect lung cancer xport-
glioblastoma ph studi eltanexor myelodysplast syndrom see trial
summari figur top-lin readout ph seal studi selinexor r/r liposarcoma like
preview week favor
top pick result
maintain compstore growth pois prove post fear misplac base check importantli
expect indic manag tini taco driven inflect compstore growth real sustain
recent momentum share
also favor
given rel low expect view increment visibl around solid qtd comp acceler
applebe abil brand deliv posit compstore growth act catalyst continu multipl
expans believ compstore growth guidanc brand would good enough sustain continu multipl
expans respect believ healthi trend post novemb price increas improv
probabl price increas end latter would result ep upsid rel expect
post-earn pullback possibl potenti present even attract opportun
recent out-performance right bake continu comp momentum nevertheless given expect
customarili conserv guidanc heel pre-announce comp manag customari retic
regard qtd trend see littl form catalyst earn respect believ qtd trend
line-to-abov consensu expect see risk consensu also believ driver compstore
growth toward least low-end guidanc tact may necessarili get specif near-term catalyst
cautiou
continu expect neg compstore growth beyond transit exclus partnership
maintain flat estim vs con await visibl perhap importantli ul
margin estim full bp consensu absent commit price increas current
run-rat view de-lever less bp unrealist
rais price target
review fire cylind
wedbush view report result handili top consensu street-high expect also
issu ebitda guidanc surpass expect high end see compani wide ebitda
guidanc rang indic high level uncertainti see high end could achiev inch
ebitda estim benefit strong start new distribut agreement
mattress firm mfrm time compani surprisingli experienc sale cannib
chang growth trajectori exist custom inde sale strength exist custom drove upsid rel
compani intern expect trend continu compani could well exceed guidanc
els equal increas distribut plu increas advertis compel product support sale growth exist
custom time compani direct channel remain solid growth ex sleep outfitt
detract growth north america also note decid conserv
financi leverag target ebtida vs previous creat option attract acquisit possibl
support stock valuat fire cylind tick estim rais target price
preview comp driver fade
wedbush view remain sidelin earn wednesday februari expect least
in-lin quarter upsid risk comp estim report basi adjust shipment time
vs consensu estim ep vs consensu estim check review promot
see review quarter easi comparison challeng outlook indic healthi sale environ
despit rise sale tempur-ped product mfrm look forward face tougher comparison includ doubl
digit order growth first half compar store sale although
sign aggress promot key presid day sell period figur expect comp growth
moder key driver growth past two year -- price/mix increas attach salesar
like slow expect bp improv impli unit comp
inde compani taken price sinc fall figur see room signific increas
refresh line reduc potenti typic boost moreov think mattress mix
materi benefit final surg attach rate adjust base associ launch line
fulli annual slow driver much comp attach rate jump bp
math elev interest expect snbr new high-end climat bed meaning
contributor compani new partnership mayo clinic take time produc financi benefit
time snbr product becom less differenti exampl tempur-ped recent launch smart base
sleep track partner snore adjust softer outlook reflect snbr initi guidanc
msd-hsd sale growth lsd comp back contribut new store extra week
initi ep guidanc approxim mid-teen growth impli lsd-hsd growth back
extra week upshot initi guidanc like conserv compani may rais
earn still think underli comp growth outlook robust underli oper profit growth
msd best growth prospect see best fairli valu ebitda
strong finish pois acceler
post strong finish acceler acv two point y/i grow backlog y/i digit
transform continu secular driver lay groundwork continu execut like continu
term licens book particularli strong custom becom comfort cloud choic provid
among three lead cloud vendor deal contain term shift revenu recognit
manag didnt specif provid acv guidanc opin acv acceler base pipelin
metric invest sale capac cloud book expect remain around new deal pave way
improv headlin metric
share trade revenu vs matur peer high-growth peer key metric
inflect posit remain top pick garp-ori softwar investor wedbush best idea
wedbush view lower expect follow dismal perform manag made good plan
drive non-hotel auction growth reign spend wednesday aftermarket trade share
thursday vs bp relief respect perform morph anxieti
surround bearish commentari estim materi given overal sell-off travel
industri recent week coronaviru news direct impact appear rel modest maintain
neutral rate lower price target equat ebitda multipl lower
estim
report adjust ebitda estim short street
versu last year versu consensu estim narrowli beat top line
margin front lower expect follow dismal perform manag made good plan drive
non-hotel auction growth reign spend
result line manag shoot idea higher invest cost
godaddi deliv mostli in-lin quarter mostli in-lin revenu guidanc book growth
consensu estim guidanc howev better investor fear
despit consist commentari manag reiter call also note call well investor
meet in-between earn invest profil compani would deviat histor trend
persist fear godaddi would begin invest heavili follow arriv ceo aman bhutani increas
focu drive veloc innov continu hear question investor manag
ask multipl time call bit perplex continu focu issu
believ concern may drive degre discount share separ note recent
uniregistri acquisit expect contribut revenu growth neutral ufcf growth
manag commit return normal custom count year in-
line expect recent run rate larg due product merchandis
custom manag also note cohort valu highest ever driven presenc
segment remain balanc share invest growth driver off-set pocket slower growth
continu see share work way fair valu assess maintain neutral rate
news report yesterday indic launch intern market bill pinterest-lik app
facebook call hobbi app recent made avail colombia belgium spain ukrain fact wsj
report earlier week facebook build sizeabl team build app intern ftc anti-trust
pressur make difficult app stand-alon integr directli facebook yet pin share
aftermarket trade yesterday news overreact news view
see meaning risk pinterest certainli see risk estim app seem
interest app center around take pictur phone save specif categori document
rememb thing love pinterest significantli complex product aim drive discoveri
inspir catalog billion pictur imag graph year interest imag graph data
strength search user data advantag around high intent purpose-driven usership inspiration-driven
platform facebook/soci media usag data similar top funnel high intent discover data
pinterest user continu see pinterest strength better tie togeth top funnel behavior shoppabl
pinterest continu push better measur convers optim new ad product longer attribut
window continu see uniqu platform year ahead new competitor platform would
competit product alway someth keep eye particularli tie togeth facebook user
base also import view advertis continu look altern facebook wall garden
pinterest continu improv option democrat ad spend on-line
chang estim price target impli ev/revenu
review data center strength boost result outlook
handili beat wedbush consensu estim better data center result sequenti drove revenu
gm bp upsid ep turn came vs estim consensu data
center momentum expect continu new product horizon could invigor growth accret
mlnx acquisit like soon final see reason shift view reiter outperform rate
lift target price reflect increas estim
data center revenu came well prior outlook anticip like
report upsid vs estim anticip magnitud growth demonstr quarter
sequenti lift exceed even increas believ enjoy cloud orient busi
moreov guidanc impli manag expect sequenti growth segment strong report
indic compani make progress close mlnx reiter expect deal
complet earli believ mlnx out-performance strong revenu gener last year
shift econom deal make favor
guid roughli headwind tie coronaviru impact predominantli factor
compani outlook game remain concern given disrupt suppli chain impact could
extens howev also believ time quarter april qtr end give time make
infrastructur challeng mlnx among compani least like space see demand destruct
shift chines consum habit toward introvers activ avoid public contact on-line order
stream video game etc like boost consumpt part either person devic pc
via consumpt cloud servic
arriv price target appli price-to-earnings plu cash multipl estim
equal estim growth core game data center gpu sale
anoth solid quarter healthi outlook cloud drive growth
report anoth beat continu cloud success margin expans cap great coupl
robust outlook compani experienc larger deal field cxone platform shift
cloud continu major tailwind adopt analyt ai offer increas point cloud
revenu acceler year year account total revenu metric expect push well
mark take ccaa cxone x-sight custom appetit serious grow x-sight enterpris
penetr smb well geograph expand emea apac current rev come
na major emphasi place analyt ai autom x-sight continu expand repres
anoth major growth opportun still larg financi institut opportun capit
well adjac market outsid financi market opportun increas regul especi
financi crime complianc area continu build data consolid robot
opinion built much broader robust cloud-bas platform importantli made right invest sales/
partner channel catalyz cloud deal flow beyond nutshel weav analyt cloud
ai capabl everi aspect product portfolio strateg endeavor continu produc
enterpris leverag differenti product portfolio accommod huge data set maintain outperform
rais price target reflect cloud strength
new ad product remain focu result guidanc expect
report lower expect guidanc revenu ebitda guidanc well
expect includ adjust ebitda margin consensu miss driven greater expect
season reduct spend smb decemb note howev trend revers januari smb
increas advertis earli year y/i growth cpc ad budget februari stori remain
squar around abil better captur multi-loc nation advertis improv retent expand
ad product complementari standard daili ad spend regard budget retent non-term
advertis mid-teen expect continu also hire david schwartzbach cfo
previous cfo optim custom optim softwar a/b test compani cfo ebay
na marketplac prior relev experi run marketplac busi help understand local smb
advertis view despit seem progress product front target set expect
path get midterm target get even tighter impli big step growth target
includ mid-teen revenu compound-annual-growth-rate vs guidanc adjust ebitda
margin vs guidanc continu see mid-term target need strong consist execut
hit product develop yet make enough impact valuat properli reflect maintain
neutral rate
set stage gain
justifi strong ytd share price run big beat above-consensu guid set stage
out-performance strong growth revenu y/i rpo y/i sustain net expans
increas penetr global point well-hon execut ayx land-and-expand model
result corrobor check point traction sign new logo appeal tri
buy model success expand relationship quarter via attract term longer durat and/
licens expect initi guidanc top consensu like leav lot room improv
given ayx obviou market momentum conserv approach guidanc
despit posit isnt without controversi durat disclosur leav wide latitud debat concern
true growth rate exist metric look suffici us valid posit view long-term dcf
indic plenti room share price upsid sustain momentum oper leverag trade
revenu share still sever turn lower high-growth peer
expect broad strength momentum pick
sciplay report end decemb result market close tuesday februari host call
pt
sciplay appear hit stride fourth quarter estim revenu adjust ebitda million
million vs consensu million million figur million million
impli revenu guidanc million reflect sequenti growth full year guidanc
million proprietari domest app store channel check indic posit trend major
game portfolio jackpot parti casino largest titl revenu saw meaning gross rank
improv appl app store median rank googl
q-o-q growth contempl guidanc appear well within reach
expect low hurdl initi revenu guidanc
estim revenu adjust ebitda million million vs consensu million
million expect sciplay guid revenu growth around y-o-i impli roughli million
rel high end guidanc rang high level commentari improv oper leverag sciplay
appear firmli on-track meet long-term profit target
hit coronaviru save drive reacceler shot fire googl
wedbush view messi pleasantli surpris optimist ramp impli full-year
guidanc equal importantli found forthright natur current manag team breath fresh air
tradit financial/tech jargon replac honest convers opportun threat face
compani well detail admiss previou misstep particular appreci manag willing call
anti-competit even anti-soci practic googl call degre govern regul
time tell prove right strategi head-on discuss major threat industri
seem least first step address threat
report adjust ebitda vs estim street gener
upsid rel consensu princip compos better profit ota
ebitda vs consensu trivago ebitda vs consensu quarter expedia report
sale growth slightli estim growth consensu forecast
estim growth ota vs street wherea vrbo vs our/th street
expect sale trivago egencia
better softwar slate last year drive sluggish start
market close thursday februari npd releas januari four-week period end februari
retail video game hardwar softwar sale data
accord npd januari console/handheld softwar sale million year-over-year in-lin
estim million larg declin driven primarili better releas slate year earlier trio game
capcom resid evil nintendo new super mario bro squar enix kingdom heart enjoy strong
debut januari contrast januari two signific consol launch bandai namco dragon ball
kakarot pc nintendo tokyo mirag session fe encor switch latter game rel
quiet debut term first month retail contribut addit headwind three januari launch
also drag digit mix shift slow current-gen xbox one cycl popular free-to-play
titl mobil momentum potenti degre franchis fatigu well
current-gen hardwar unit sale year-over-year januari well expect across board
roughli unit sold versu unit estim roughli xbox one unit sold
versu unit estim roughli nintendo switch unit sold versu unit estim
switch sell well expect note recent uptick switch advertis
strengthen demand devic futur period switch led industri unit sale fourteenth consecut month
driven switch posit momentum multipl game
dream dream
clearli tremend opportun revenu growth well-posit benefit rise stream
servic cord cut global focus expand licens partnership drive advertis revenu
growth channel advertis video demand avod partner said path
profit unclear continu expand workforc support next leg growth achiev profit
roku intern market take time view like rein roku lofti valuat becom clear
investor clearli substanti growth opportun think multipl alreadi stretch therefor
maintain neutral rate rais target slightli
result beat guidanc sold player cost
revenu million vs estim million consensu million guidanc million
adjust ebitda million vs estim million consensu million guidanc million non-
loss per share vs estim consensu signific expans stream
option includ disney drove increas cord-cut quarter acceler activ account
growth platform excess estim rel model player revenu drove revenu
beat sold break-even quarter player gross margin guidanc suggest player
revenu littl room expans platform revenu two-third revenu expect
constitut three-quart revenu impli minim growth player sale zero margin
compani cover respect research analyst analyst certifi view express research report
accur reflect research analyst person view subject secur compani part
compens directli indirectli relat specif recommend view contain research report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
februari
februari
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
